Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

After years of delays and debate, 2024 was the year when several health initiatives started to move forward. And advocates ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

More than 110,000 North Carolinians are projected to benefit from a $2,000 annual cap on out-of-pocket costs for covered prescription drugs for Medicare Part D participants.

Medicare, in collaboration with Medicaid, has negotiated with pharmaceutical companies to reduce the prices of ten high-cost, ...

SGLT-2 inhibitors include empagliflozin (Jardiance) and dapagliflozin (Farxiga), and GLP-1 agonists include semaglutide (Ozempic) and liraglutide (Victoza). "The use of these evidence-based ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

With list prices of $8.94 per day for the monotherapy and metformin combinations, the companies are hoping to gain ground on Farxiga and Jardiance by undercutting them – Farxiga costs $11.57 per ...

Under the IRA, companies that refuse to reduce prices risk an excise tax starting ... became clear that its big-selling diabetes treatment Jardiance (empagliflozin) – sold with Eli Lilly ...

GLP-1 drugs, including Ozempic, Monjauro and Rybelsus, treat type 2 diabetes. The drugs can cost more than $1,000 a month SGLT-2 drugs include Jardiance, Farxiga and Invokana. Here are five numbers to ...